Drug Profile
Senaparib - IMPACT Therapeutics
Alternative Names: IMP-4297; JS-109Latest Information Update: 24 Oct 2023
Price :
$50
*
At a glance
- Originator IMPACT Therapeutics
- Class Antineoplastics; Fluorobenzenes; Piperazines; Pyrimidines; Quinazolinones; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Ovarian cancer
- Phase I/II Small cell lung cancer; Solid tumours
- Phase I Prostate cancer
Most Recent Events
- 24 Oct 2023 Safety and efficacy data from a phase Ib/II trial in Solid tumours and Small cell lung cancer presented at the 24th World Conference on Lung Cancer (ECLC-2023)
- 20 Oct 2023 Efficacy and adverse events data from the phase II SABRINA trial in Ovarian cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 20 Oct 2023 Efficacy and adverse events data from the phase III FLAMES trial in Ovarian cancer presented at the (48th European Society for Medical Oncology Congress (ESMO-2023)